BRISBANE, Calif.--(BUSINESS WIRE)-- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will host a symposium to describe the latest innovations in post-cardiac transplant care at the HFSA (Heart Failure Society of America) Annual Scientific Meeting 2022 taking place in Washington, D.C., September 30 - October 3.

“We look forward to HFSA where we will share more on our AI Heart Platform with AiCAV™, a new offering in development that will help to inform clinicians in their assessment of cardiac allograft vasculopathy risk,” said Reg Seeto, CEO and President of CareDx. “For over two decades, CareDx has been leading innovation to improve outcomes for transplant patients and we are extremely proud to extend this leadership with AiKidney™ and AiCAV.”

“It is gratifying to work with CareDx to advance our shared mission of improving long-term graft and recipient health through the use of HeartCare multimodal assessments which have been transformative in driving much earlier interventions to reduce the risk of organ injury and drug toxicity,” said Claudia Gidea, MD, Medical Director, Heart Transplant and LVAD Program, Mount Sinai Health System. “CareDx has been a driving force in multimodal innovation, and I look forward to attending HFSA and learning more about their latest advances and how they might be incorporated for patients that have increasingly complex comorbidities and for patients with multiorgan transplantation.”

CareDx will host the symposium, “Future of Post-Cardiac Transplant Care: Strategies to Predict and Improve Outcomes,” on Sunday, October 2 from 5:30-7:00pm EST. Presentations and speakers include the following:

• Heart Transplant Surveillance: Challenge Accepted! Jeremy Kobulnik, MD, Heart Transplant, Medical Director, CareDx
• Building a Successful Transplant Program: Keys to Success. Shelley Hall, MD, Baylor Scott & White Health
• Evolving the Surveillance of Heart Transplant Rejection – A Multi-modal Approach. Amit Alam, MD, Baylor Scott & White Health
• Shifting to Predictive Models for Outcomes in Heart Transplantation. Jon Kobashigawa, MD, Cedars-Sinai Medical Center

AlloMap® became commercially available in 2005 and has the distinction of being the only gene-expression profiling test that has been FDA cleared for use in heart transplant patients,¹ incorporated in International Society for Heart and Lung Transplantation guidelines and covered by Centers for Medicare & Medicaid Services (CMS) both individually and for multimodality assessment using AlloSure® donor-derived cell-free DNA. AlloMap is used in more than 90 percent of the nation’s heart transplant centers and in more than 1 in 2 newly transplanted patients.² In 2020, CareDx launched HeartCare, which includes both AlloMap and AlloSure, to provide a comprehensive view of organ rejection by assessing immune quiescence and graft injury, and currently accounts for over 90 percent of AlloMap use.²

About CareDx – The Transplant Company

CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

Forward Looking Statements

This press release includes forward-looking statements related to CareDx, Inc., including statements regarding the potential benefits and results that may be achieved with CareDx becoming a top-tier sponsor for HFSA 2022 Meeting and hosting the symposium in such meeting (collectively, the “HFSA Participation”). These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including risks that CareDx does not realize the expected benefits of its HFSA Participation; risks that the HFSA 2022 Meeting and CareDx’s symposium fail to take place at the time and place or discuss the topics as shown in the press release; general economic and market factors; and other risks discussed in CareDx’s filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed by CareDx with the SEC on February 24, 2022, the quarterly report on Form 10-Q for the quarter ended March 31, 2022 filed by CareDx with the SEC on May 5, 2022, the quarterly report on Form 10-Q for the quarter ended June 30, 2022 filed by CareDx with the SEC on August 4, 2022, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx’s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.

References:

1. AlloMap Testing is intended to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection (ACR) at the time of testing in conjunction with standard clinical assessment.
2. CareDx data on file, September 15, 2022.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220929005300/en/